<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292875</url>
  </required_header>
  <id_info>
    <org_study_id>TG002B</org_study_id>
    <nct_id>NCT02292875</nct_id>
  </id_info>
  <brief_title>ToleroMune Grass Follow on Study</brief_title>
  <official_title>An Optional Follow-Up Study to Evaluate the Continued Efficacy of ToleroMune Grass in Grass Allergic Subjects Following Challenge With Grass Allergen in an Environmental Exposure Unit.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Grass pollen allergens are recognised as a major cause of allergic diseases in humans and&#xD;
      animals. Worldwide, at least 40% of allergic patients are sensitised to grass pollen&#xD;
      allergens and between 50-90% of hayfever or seasonal allergy sufferers are allergic to grass&#xD;
      pollen. ToleroMune Grass is a novel, synthetic, allergen-derived peptide desensitising&#xD;
      vaccine, currently being developed for the treatment of grass allergy.&#xD;
&#xD;
      The purpose of this optional observational follow-on study is to further evaluate&#xD;
      rhinoconjunctivitis symptoms on exposure to Grass in the EEU among subjects who completed all&#xD;
      dosing visits in study TG002 approximately two years after the start of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a follow-up study to a multi-centre, randomised, double-blind, placebo controlled,&#xD;
      parallel group clinical study (TG002) which evaluated the efficacy, safety and tolerability&#xD;
      of three doses of ToleroMune Grass versus placebo in grass allergic subjects. Subjects who&#xD;
      completed TG002 in calendar year 2012 will undergo a further single exposure to grass&#xD;
      allergens in an EEU.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Total Rhinoconjunctivitis Symptom Scores</measure>
    <time_frame>32 months post first dose in TG002</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Grass Specific Immunoglobulin A (IgA)</measure>
    <time_frame>32 months post first dose in TG002</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass Specific Immunoglobulin E (IgE)</measure>
    <time_frame>32 months post first dose in TG002</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grass Specific Immunoglobulin G Isotype 4 (IgG4)</measure>
    <time_frame>32 months post first dose in TG002</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin Prick Weal Diameter</measure>
    <time_frame>32 months post first dose in TG002</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>32 months post first dose in TG002</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">84</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <condition>Grass Allergy</condition>
  <arm_group>
    <arm_group_label>TG002 Subjects</arm_group_label>
    <description>Subjects previously randomised in study TG002</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subject previously randomised in study TG002 and completed all dosing visits and the PTC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously randomised into study TG002, and completed all treatment visits and PTC&#xD;
             during calendar year 2012&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &quot;Partly controlled&quot; and &quot;uncontrolled&quot; asthama&#xD;
&#xD;
          -  History of anaphylaxis to grass allergen&#xD;
&#xD;
          -  FEV1 &lt;80% of predicted&#xD;
&#xD;
          -  Treatment with beta-blockers, alpha-adrenoreceptor blockers, tranquilizers or&#xD;
             psychoactuve drugs&#xD;
&#xD;
          -  Symptoms of a clinically relevant illness&#xD;
&#xD;
          -  Subjects who cannot tolerate allergen challenge in the EEU&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Kanata</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>November 14, 2014</last_update_submitted>
  <last_update_submitted_qc>November 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Grass Allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <keyword>Environmental Exposure Unit</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>ToleroMune Grass</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

